Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma:

Chengming Liu; Sufei Zheng; Sihui Wang; Xinfeng Wang; Xiaoli Feng; Nan Sun; Jie He

doi:10.1177/17588359211006949

Liu, Chengming; Zheng, Sufei; Wang, Sihui; Wang, Xinfeng; Feng, Xiaoli; Sun, Nan; He, Jie

2021-04-08 00:00:00

Background: EGFR mutation is a common oncogene driver in East Asians with lung adenocarcinoma (LUAD), conferring a favorable prognosis with effective targeted therapy. However, the EGFR mutation is a weak predictor of long-term survival. Therefore, a powerful predictive tool is urgently needed to estimate disease prognosis and patient survival for East-Asian patients with LUAD. Methods: In this first systematic analysis of the relationships among EGFR mutation, immunophenotype, and prognosis in LUAD samples from East-Asian patients, we constructed a prognostic signature consisting of EGFR-associated immune-related gene pairs (EIGPs). The predictive performance for overall survival (OS) and the clinical significance of this signature were then comprehensively investigated. Results: Based on transcriptome data analysis of a training set, we proposed the EIGP index (EIGPI), represented by five EIGPs, which was significantly associated with the OS of East-Asian patients with LUAD. It was also well validated in a test set. Furthermore, the prognostic performance of the EIGPI was further verified using protein levels in an additional independent set. Stratification analysis and multivariate Cox regression analysis revealed that the EIGPI was an independent prognostic factor. When combined with stage, the composite immune-clinical prognostic model index (ICPMI) showed improved prognostic accuracy in all datasets. Conclusion: This study was the first to systematically investigate the relationships among EGFR mutation, immunophenotype, and prognosis in East Asians with LUAD and develop a composite clinical and immune model associated with EGFR mutation. This model may be a reliable and promising prognostic tool and help further personalize patient management.

http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Therapeutic Advances in Medical Oncology SAGE

http://www.deepdyve.com/lp/sage/development-and-external-validation-of-a-composite-immune-clinical-CLF3lS5nED

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma:

Liu, Chengming; Zheng, Sufei; Wang, Sihui; Wang, Xinfeng; Feng, Xiaoli;

Therapeutic Advances in Medical Oncology , Volume 13: 1 – Apr 8, 2021

Abstract

References (113)

( ShigematsuHLinLTakahashiT, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–346.15741570)

ShigematsuHLinLTakahashiT, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–346.15741570

ShigematsuHLinLTakahashiT, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–346.15741570, ShigematsuHLinLTakahashiT, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–346.15741570

The prognostic landscape of genes and infiltrating immune cells across human cancers

Michael Gillette, S. Satpathy, Song Cao, S. Dhanasekaran, S. Vasaikar, Karsten Krug, F. Petralia, Y. Li, Wen-Wei Liang, B. Reva, R. Hong, Sara Savage, G. Getz, Q. Li, Bing Zhang, H. Rodriguez, Kelly Ruggles, A. Robles, K. Clauser, R. Govindan, Pei Wang, A. Nesvizhskii, L. Ding, D. Mani, S. Carr (2020)

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Cell, 182

J. Long, Anqiang Wang, Yi Bai, Jianzhen Lin, Xu Yang, Dongxu Wang, Xiaobo Yang, Yan Jiang, Haitao Zhao (2019)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma

EBioMedicine, 42

( SuSDongZ-YXieZ, et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J Thorac Oncol 2018; 13: 1668–1675.30056164)

SuSDongZ-YXieZ, et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J Thorac Oncol 2018; 13: 1668–1675.30056164, SuSDongZ-YXieZ, et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J Thorac Oncol 2018; 13: 1668–1675.30056164

Yi-Ju Chen, T. Roumeliotis, Ya‐Hsuan Chang, Ching-Tai Chen, Chia-Li Han, Miao-Hsia Lin, Huei-Wen Chen, G. Chang, Yih-Leong Chang, Chen‐Tu Wu, Mong-Wei Lin, Min-Shu Hsieh, Yu-Tai Wang, Yet-Ran Chen, I. Jonassen, F. Ghavidel, Ze-Shiang Lin, Kuen-Tyng Lin, Ching-Wen Chen, P. Sheu, Chen-Ting Hung, Kefei Huang, Hao Yang, Pei-Yi Lin, T. Yen, Yi-Wei Lin, Jen-Hung Wang, Lovely Raghav, Chien-Yu Lin, Yan-Si Chen, Pei-Shan Wu, Chih-Ting Lai, Shao-Hsing Weng, K. Su, Wei-Hung Chang, P. Tsai, A. Robles, H. Rodriguez, Yi-Jing Hsiao, Wen-Hsin Chang, Ting-Yi Sung, Jin-Shing Chen, Sung-Liang Yu, J. Choudhary, Hsuan-Yu Chen, Pan‐Chyr Yang, Yu-Ju Chen (2020)

Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression

Cell, 182

( Clinical Lung Cancer Genome Project; Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.)

Clinical Lung Cancer Genome Project; Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.

Clinical Lung Cancer Genome Project; Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153., Clinical Lung Cancer Genome Project; Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.

T. Cheng, S. Cramb, P. Baade, D. Youlden, C. Nwogu, M. Reid (2016)

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Journal of Thoracic Oncology, 11

Y. Hoshida, Jean-Philippe Brunet, P. Tamayo, T. Golub, J. Mesirov (2007)

Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets

PLoS ONE, 2

( PapkeBDerCJ. Drugging RAS: know the enemy. Science 2017; 355: 1158–1163.28302824)

PapkeBDerCJ. Drugging RAS: know the enemy. Science 2017; 355: 1158–1163.28302824

PapkeBDerCJ. Drugging RAS: know the enemy. Science 2017; 355: 1158–1163.28302824, PapkeBDerCJ. Drugging RAS: know the enemy. Science 2017; 355: 1158–1163.28302824

( SimonNFriedmanJHastieT, et al. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw 2011; 39: 1–13.)

SimonNFriedmanJHastieT, et al. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw 2011; 39: 1–13.

SimonNFriedmanJHastieT, et al. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw 2011; 39: 1–13., SimonNFriedmanJHastieT, et al. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw 2011; 39: 1–13.

( GilletteMASatpathySCaoS, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 2020; 182: 200–225.e35.)

GilletteMASatpathySCaoS, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 2020; 182: 200–225.e35.

GilletteMASatpathySCaoS, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 2020; 182: 200–225.e35., GilletteMASatpathySCaoS, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 2020; 182: 200–225.e35.

( SudaKMitsudomiT. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Arch Toxicol 2015; 89: 1227–1240.25983263)

SudaKMitsudomiT. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Arch Toxicol 2015; 89: 1227–1240.25983263

SudaKMitsudomiT. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Arch Toxicol 2015; 89: 1227–1240.25983263, SudaKMitsudomiT. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Arch Toxicol 2015; 89: 1227–1240.25983263

( HaimanCAStramDOWilkensLR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333–342.16436765)

HaimanCAStramDOWilkensLR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333–342.16436765

HaimanCAStramDOWilkensLR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333–342.16436765, HaimanCAStramDOWilkensLR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333–342.16436765

T. Lee, F. Gany (2013)

Cooking Oil Fumes and Lung Cancer: A Review of the Literature in the Context of the U.S. Population

Journal of Immigrant and Minority Health, 15

( CampbellJDAlexandrovAKimJ, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016; 48: 607–616.27158780)

CampbellJDAlexandrovAKimJ, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016; 48: 607–616.27158780

CampbellJDAlexandrovAKimJ, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016; 48: 607–616.27158780, CampbellJDAlexandrovAKimJ, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016; 48: 607–616.27158780

( SeowAPohWTTehM, et al. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 1215–1221.11097230)

SeowAPohWTTehM, et al. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 1215–1221.11097230

SeowAPohWTTehM, et al. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 1215–1221.11097230, SeowAPohWTTehM, et al. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 1215–1221.11097230

( WuKZhangXLiF, et al. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun 2015; 6: 10131.)

WuKZhangXLiF, et al. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun 2015; 6: 10131.

WuKZhangXLiF, et al. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun 2015; 6: 10131., WuKZhangXLiF, et al. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun 2015; 6: 10131.

A. Seow, W. Poh, M. Teh, Philip Eng, Yee‐Tang Wang, W. Tan, Mimi Yu, Hin‐Peng Lee (2000)

Fumes from meat cooking and lung cancer risk in Chinese women.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 9 11

Kevin Wood, T. Hensing, Raeva Malik, R. Salgia (2016)

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.

JAMA oncology, 2 6

E. Jordan, H. Kim, M. Arcila, D. Barron, D. Chakravarty, Jianjiong Gao, Matthew Chang, A. Ni, Ritika Kundra, P. Jonsson, G. Jayakumaran, S. Gao, Hannah Johnsen, Aphrothiti Hanrahan, A. Zehir, N. Rekhtman, M. Ginsberg, Bob Li, H. Yu, P. Paik, A. Drilon, M. Hellmann, D. Reales, R. Benayed, V. Rusch, M. Kris, J. Chaft, J. Baselga, B. Taylor, N. Schultz, C. Rudin, D. Hyman, M. Berger, D. Solit, M. Ladanyi, Gregory Riely (2017)

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Cancer discovery, 7 6

M. Kris, B. Johnson, L. Berry, D. Kwiatkowski, A. Iafrate, I. Wistuba, M. Varella-Garcia, W. Franklin, S. Aronson, P. Su, Y. Shyr, D. Camidge, L. Sequist, B. Glisson, F. Khuri, E. Garon, W. Pao, C. Rudin, J. Schiller, E. Haura, M. Socinski, K. Shirai, Heidi Chen, G. Giaccone, M. Ladanyi, K. Kugler, J. Minna, P. Bunn (2014)

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

JAMA, 311 19

( LiuCZhengSJinR, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. Epub ahead of print 20 October 2019. DOI: 10.1016/j.canlet.2019.10.027.)

LiuCZhengSJinR, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. Epub ahead of print 20 October 2019. DOI: 10.1016/j.canlet.2019.10.027., LiuCZhengSJinR, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. Epub ahead of print 20 October 2019. DOI: 10.1016/j.canlet.2019.10.027.

( ChenYJRoumeliotisTIChangYH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell 2020; 182: 226–244.e17.)

ChenYJRoumeliotisTIChangYH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell 2020; 182: 226–244.e17.

ChenYJRoumeliotisTIChangYH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell 2020; 182: 226–244.e17., ChenYJRoumeliotisTIChangYH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell 2020; 182: 226–244.e17.

( LiuX-XYangY-ELiuX, et al. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med 2019; 17: 50.30777071)

LiuX-XYangY-ELiuX, et al. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med 2019; 17: 50.30777071

LiuX-XYangY-ELiuX, et al. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med 2019; 17: 50.30777071, LiuX-XYangY-ELiuX, et al. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med 2019; 17: 50.30777071

M. Ito, Y. Miyata, K. Kushitani, T. Yoshiya, Y. Kai, Y. Tsutani, T. Mimura, K. Konishi, Y. Takeshima, M. Okada (2018)

Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma

Thoracic Cancer, 9

M. Love, W. Huber, S. Anders (2014)

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Genome Biology, 15

D. Seidel, T. Zander, L. Heukamp, M. Peifer, M. Bos, L. Fernandez-Cuesta, F. Leenders, Xin Lu, S. Ansén, M. Gardizi, C. Nguyen, J. Berg, P. Russell, Z. Wainer, H. Schildhaus, Toni-Maree Rogers, B. Solomon, W. Pao, S. Carter, G. Getz, D. Hayes, M. Wilkerson, E. Thunnissen, W. Travis, S. Perner, Gavin Wright, E. Brambilla, R. Buettner, J. Wolf, Roman Thomas, F. Gabler, Ines Wilkening, C. Mueller, Ilona Dahmen, R. Menon, Katharina Koenig, K. Albus, S. Merkelbach-Bruse, J. Fassunke, K. Schmitz, Helen Kuenstlinger, M. Kleine, E. Binot, S. Querings, J. Altmueller, Ingelore Boessmann, Peter Nuemberg, P. Schneider, Magdalena Bogus, A. Soltermann, H. Moch, O. Brustugun, S. Solberg, M. Lund-Iversen, Å. Helland, T. Muley, H. Hoffmann, P. Schnabel, Yuan-Hua Chen, H. Groen, W. Timens, H. Sietsma, J. Clement, W. Weder, J. Saenger, E. Stoelben, C. Ludwig, W. Engel‐Riedel, E. Smit, D. Heideman, P. Snijders, L. Nogova, M. Sos, C. Mattonet, K. Toepelt, M. Scheffler, E. Goekkurt, R. Kappes, S. Krueger, K. Kambartel, D. Behringer, W. Schulte, W. Galetke, W. Randerath, M. Heldwein, A. Schlesinger, M. Serke, K. Hekmat, K. Frank, R. Schnell, M. Reiser, Ali-Nuri Huenerlituerkoglu, S. Schmitz, L. Meffert, Y. Ko, Markus Litt-Lampe, U. Gerigk, R. Fricke, B. Besse, C. Brambilla, S. Lantuejoul, P. Lorimier, D. Moro-Sibilot, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, R. Hyde, P. Validire, P. Girard, L. Muscarella, V. Fazio, M. Hallek, J. Soria, V. Achter, Ulrich Lang (2013)

A Genomics-Based Classification of Human Lung Tumors

Science Translational Medicine, 5

N. Simon, J. Friedman, T. Hastie, R. Tibshirani (2011)

Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent.

Journal of statistical software, 39 5

Chen Wu, Zhibin Hu, Dianke Yu, Liming Huang, G. Jin, Jie Liang, Huan Guo, W. Tan, Mingfeng Zhang, J. Qian, D. Lu, Tangchun Wu, D. Lin, Hongbing Shen (2009)

Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations.

Cancer research, 69 12

( BhattacharyaSAndorfSGomesL, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014; 58: 234–239.24791905)

BhattacharyaSAndorfSGomesL, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014; 58: 234–239.24791905

BhattacharyaSAndorfSGomesL, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014; 58: 234–239.24791905, BhattacharyaSAndorfSGomesL, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014; 58: 234–239.24791905

A. Gentles, Aaron Newman, C. Liu, S. Bratman, Weiguo Feng, Dongkyoon Kim, V. Nair, Yue Xu, Amanda Khuong, Chuong Hoang, M. Diehn, R. West, S. Plevritis, Ash Alizadeh (2015)

Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers

Cancer Research, 75

B. Osta, M. Behera, Sungjin Kim, L. Berry, G. Sica, R. Pillai, T. Owonikoko, M. Kris, B. Johnson, D. Kwiatkowski, P. Bunn, F. Khuri, S. Ramalingam (2017)

Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.

Journal of Clinical Oncology, 35

( DongZYZhangJTLiuSY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017; 6: e1356145.)

DongZYZhangJTLiuSY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017; 6: e1356145., DongZYZhangJTLiuSY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017; 6: e1356145.

( LiBCuiYDiehnM, et al. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 2017; 3: 1529–1537.28687838)

LiBCuiYDiehnM, et al. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 2017; 3: 1529–1537.28687838

LiBCuiYDiehnM, et al. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 2017; 3: 1529–1537.28687838, LiBCuiYDiehnM, et al. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 2017; 3: 1529–1537.28687838

( LeeTGanyF. Cooking oil fumes and lung cancer: a review of the literature in the context of the U.S. population. J Immigr Minor Health 2013; 15: 646–652.22678304)

LeeTGanyF. Cooking oil fumes and lung cancer: a review of the literature in the context of the U.S. population. J Immigr Minor Health 2013; 15: 646–652.22678304

LeeTGanyF. Cooking oil fumes and lung cancer: a review of the literature in the context of the U.S. population. J Immigr Minor Health 2013; 15: 646–652.22678304, LeeTGanyF. Cooking oil fumes and lung cancer: a review of the literature in the context of the U.S. population. J Immigr Minor Health 2013; 15: 646–652.22678304

( KrisMGJohnsonBEBerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998–2006.24846037)

KrisMGJohnsonBEBerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998–2006.24846037

KrisMGJohnsonBEBerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998–2006.24846037, KrisMGJohnsonBEBerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998–2006.24846037

( WangJLiuQYuanS, et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep 2017; 7: 8371.28827732)

WangJLiuQYuanS, et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep 2017; 7: 8371.28827732, WangJLiuQYuanS, et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep 2017; 7: 8371.28827732

( BrayFFerlayJSoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.30207593)

BrayFFerlayJSoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.30207593, BrayFFerlayJSoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.30207593

K. Miller, Leticia Nogueira, A. Mariotto, J. Rowland, K. Yabroff, C. Alfano, A. Jemal, J. Kramer, R. Siegel (2019)

Cancer treatment and survivorship statistics, 2019

CA: A Cancer Journal for Clinicians, 69

( WuCHuZYuD, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res 2009; 69: 5065–5072.19491260)

WuCHuZYuD, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res 2009; 69: 5065–5072.19491260

WuCHuZYuD, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res 2009; 69: 5065–5072.19491260, WuCHuZYuD, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res 2009; 69: 5065–5072.19491260

( ChenJYangHTeoASM, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 2020; 52: 177–186.32015526)

ChenJYangHTeoASM, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 2020; 52: 177–186.32015526

ChenJYangHTeoASM, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 2020; 52: 177–186.32015526, ChenJYangHTeoASM, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 2020; 52: 177–186.32015526

( DeardenSStevensJWuY-L, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371–2376.23723294)

DeardenSStevensJWuY-L, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371–2376.23723294

DeardenSStevensJWuY-L, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371–2376.23723294, DeardenSStevensJWuY-L, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371–2376.23723294

( PengFWangRZhangY, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer 2017; 16: 98.28587642)

PengFWangRZhangY, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer 2017; 16: 98.28587642

PengFWangRZhangY, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer 2017; 16: 98.28587642, PengFWangRZhangY, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer 2017; 16: 98.28587642

( ImielinskiMBergerAHHammermanPS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107–1120.22980975)

ImielinskiMBergerAHHammermanPS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107–1120.22980975

ImielinskiMBergerAHHammermanPS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107–1120.22980975, ImielinskiMBergerAHHammermanPS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107–1120.22980975

Bailiang Li, Yi Cui, M. Diehn, Ruijiang Li (2017)

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer

JAMA Oncology, 3

F. Peng, Ruiping Wang, Yuanyuan Zhang, Zhangxiang Zhao, Wenbin Zhou, Zhiqiang Chang, Haihai Liang, Wenyuan Zhao, L. Qi, Zheng Guo, Yunyan Gu (2017)

Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma

Molecular Cancer, 16

( ShuklaSEvansJRMalikR, et al. Development of a RNA-seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 2017; 109: djw200.)

ShuklaSEvansJRMalikR, et al. Development of a RNA-seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 2017; 109: djw200.

ShuklaSEvansJRMalikR, et al. Development of a RNA-seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 2017; 109: djw200., ShuklaSEvansJRMalikR, et al. Development of a RNA-seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 2017; 109: djw200.

Chaoqi Zhang, Zhen Zhang, Guochao Zhang, Zhihui Zhang, Yuejun Luo, Feng Wang, Sihui Wang, Y. Che, Q. Zeng, N. Sun, Jie He (2020)

Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.

Cancer letters

Caicun Zhou, Yi-long Wu, Gongyan Chen, Jifeng Feng, Xiao‐qing Liu, Chang-li Wang, Shucai Zhang, Jie Wang, Songwen Zhou, S. Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, M. Ye, Jianan Huang, X. Zhi, Yiping Zhang, Q. Xiu, Jun Ma, C. You (2011)

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

The Lancet. Oncology, 12 8

Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng, Kun-Chieh Chen, Wen‐Hui Ku, K. Su, Jeremy Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, G. Chang (2019)

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.

Lung cancer, 127

Sanchita Bhattacharya, Sandra Andorf, Linda Gomes, P. Dunn, Henry Schaefer, J. Pontius, Patty Berger, Vince Desborough, Thomas Smith, John Campbell, Elizabeth Thomson, Ruth Monteiro, Patricia Guimaraes, Bryan Walters, Jeffrey Wiser, A. Butte (2014)

ImmPort: disseminating data to the public for the future of immunology

Immunologic Research, 58

( HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230)

HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230

HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230, HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230

Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas

F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA: A Cancer Journal for Clinicians, 68

Bjoern Papke, C. Der (2017)

Drugging RAS: Know the enemy

Science, 355

( LoveMIHuberWAndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.25516281)

LoveMIHuberWAndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.25516281

LoveMIHuberWAndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.25516281, LoveMIHuberWAndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.25516281

( Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543–550.25079552)

Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543–550.25079552

Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543–550.25079552, Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543–550.25079552

( EttingerDSAisnerDLWoodDE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16: 807–821.30006423)

EttingerDSAisnerDLWoodDE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16: 807–821.30006423

EttingerDSAisnerDLWoodDE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16: 807–821.30006423, EttingerDSAisnerDLWoodDE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16: 807–821.30006423

Xiaoxia Liu, Yie Yang, Xiao Liu, Mengyu Zhang, Rui Li, Yunhong Yin, Y. Qu (2019)

A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma

Journal of Translational Medicine, 17

( GarnerHde VisserKE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 2020; 20: 483–497.32024984)

GarnerHde VisserKE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 2020; 20: 483–497.32024984

GarnerHde VisserKE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 2020; 20: 483–497.32024984, GarnerHde VisserKE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 2020; 20: 483–497.32024984

(2015)

The nonsmall cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome

( XuJYZhangCWangX, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 2020; 182: 245–261.e17.)

XuJYZhangCWangX, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 2020; 182: 245–261.e17.

XuJYZhangCWangX, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 2020; 182: 245–261.e17., XuJYZhangCWangX, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 2020; 182: 245–261.e17.

Jing Sun, Tianyu Zhao, Di Zhao, Xin Qi, Xuanwen Bao, Run Shi, Chuan Su (2020)

Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients

Therapeutic Advances in Medical Oncology, 12

Hannah Garner, K. Visser (2020)

Immune crosstalk in cancer progression and metastatic spread: a complex conversation

Nature Reviews Immunology, 20

D. Ettinger, D. Aisner, D. Wood, W. Akerley, J. Bauman, Joe Chang, L. Chirieac, T. D’amico, T. Dilling, M. Dobelbower, R. Govindan, M. Gubens, M. Hennon, L. Horn, R. Lackner, M. Lanuti, T. Leal, R. Lilenbaum, Jules Lin, B. Loo, R. Martins, G. Otterson, S. Patel, K. Reckamp, Gregory Riely, S. Schild, T. Shapiro, J. Stevenson, S. Swanson, K. Tauer, Stephen Yang, K. Gregory, M. Hughes (2018)

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Journal of the National Comprehensive Cancer Network : JNCCN, 16 7

( OstaBEEBeheraMKimS, et al. Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database. J Clin Oncol 2017; 35: 9021.)

OstaBEEBeheraMKimS, et al. Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database. J Clin Oncol 2017; 35: 9021., OstaBEEBeheraMKimS, et al. Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database. J Clin Oncol 2017; 35: 9021.

( AngellHGalonJ. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261–267.23579076)

AngellHGalonJ. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261–267.23579076

AngellHGalonJ. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261–267.23579076, AngellHGalonJ. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261–267.23579076

( HsuK-HHuangY-HTsengJ-S, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer 2019; 127: 37–43.30642549)

HsuK-HHuangY-HTsengJ-S, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer 2019; 127: 37–43.30642549, HsuK-HHuangY-HTsengJ-S, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer 2019; 127: 37–43.30642549

( GentlesAJNewmanAMLiuCL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21: 938–945.26193342)

GentlesAJNewmanAMLiuCL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21: 938–945.26193342

GentlesAJNewmanAMLiuCL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21: 938–945.26193342, GentlesAJNewmanAMLiuCL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21: 938–945.26193342

( YoshizawaASumiyoshiSSonobeM, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8: 52–61.23242438)

YoshizawaASumiyoshiSSonobeM, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8: 52–61.23242438, YoshizawaASumiyoshiSSonobeM, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8: 52–61.23242438

K. Suda, T. Mitsudomi (2015)

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

Archives of Toxicology, 89

(2012)

Identification of genes upregulated in ALK-positive and EGFR/ Therapeutic Advances in Medical Oncology 13 16 journals.sagepub.com/home/tam KRAS/ALK-negative lung adenocarcinomas

( MaoSLiYLuZ, et al. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020; 43: 681–694.32462608)

MaoSLiYLuZ, et al. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020; 43: 681–694.32462608

MaoSLiYLuZ, et al. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020; 43: 681–694.32462608, MaoSLiYLuZ, et al. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020; 43: 681–694.32462608

( BatesJPDerakhshandehRJonesL, et al. Mechanisms of immune evasion in breast cancer. BMC Cancer 2018; 18: 556.29751789)

BatesJPDerakhshandehRJonesL, et al. Mechanisms of immune evasion in breast cancer. BMC Cancer 2018; 18: 556.29751789

BatesJPDerakhshandehRJonesL, et al. Mechanisms of immune evasion in breast cancer. BMC Cancer 2018; 18: 556.29751789, BatesJPDerakhshandehRJonesL, et al. Mechanisms of immune evasion in breast cancer. BMC Cancer 2018; 18: 556.29751789

H. Angell, J. Galon (2013)

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer.

Current opinion in immunology, 25 2

S. Su, Z. Dong, Z. Xie, Li-xu Yan, Yu‐Fa Li, J. Su, S. Liu, K. Yin, Rui-lian Chen, Shu-Mei Huang, Zhi-hong Chen, Jin-Ji Yang, H. Tu, Qing Zhou, W. Zhong, Xuchao Zhang, Yi-long Wu (2018)

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Journal of Thoracic Oncology, 13

Shuangshuang Mao, Yuan Li, Zhiliang Lu, Y. Che, Jianbing Huang, Yuanyuan Lei, Yalong Wang, Xinfeng Wang, Chengming Liu, Sufei Zheng, Ning Li, Jiagen Li, N. Sun, Jie He (2020)

Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma

Cellular Oncology

( LongJWangABaiY, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 2019; 42: 363–374.30885723)

LongJWangABaiY, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 2019; 42: 363–374.30885723

LongJWangABaiY, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 2019; 42: 363–374.30885723, LongJWangABaiY, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 2019; 42: 363–374.30885723

( ChengTYCrambSMBaadePD, et al. The International Epidemiology of Lung Cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016; 11: 1653–1671.27364315)

ChengTYCrambSMBaadePD, et al. The International Epidemiology of Lung Cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016; 11: 1653–1671.27364315

ChengTYCrambSMBaadePD, et al. The International Epidemiology of Lung Cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016; 11: 1653–1671.27364315, ChengTYCrambSMBaadePD, et al. The International Epidemiology of Lung Cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016; 11: 1653–1671.27364315

( IsakaTNakayamaHItoH, et al. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer 2018; 18: 959.30290774)

IsakaTNakayamaHItoH, et al. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer 2018; 18: 959.30290774, IsakaTNakayamaHItoH, et al. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer 2018; 18: 959.30290774

( JordanEJKimHRArcilaME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017; 7: 596–609.28336552)

JordanEJKimHRArcilaME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017; 7: 596–609.28336552, JordanEJKimHRArcilaME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017; 7: 596–609.28336552

( AlsaleemMABallGTossMS, et al. A novel prognostic two-gene signature for triple negative breast cancer. Mod Pathol 2020; 33: 2208–2220.32404959)

AlsaleemMABallGTossMS, et al. A novel prognostic two-gene signature for triple negative breast cancer. Mod Pathol 2020; 33: 2208–2220.32404959

AlsaleemMABallGTossMS, et al. A novel prognostic two-gene signature for triple negative breast cancer. Mod Pathol 2020; 33: 2208–2220.32404959, AlsaleemMABallGTossMS, et al. A novel prognostic two-gene signature for triple negative breast cancer. Mod Pathol 2020; 33: 2208–2220.32404959

H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Journal of the National Cancer Institute, 97 5

Eric Be, Eric Be, E. Collisson, Joshua Campbell, Angela Brooks, A. Berger, William Lee, J. Chmielecki, D. Beer, L. Cope, C. Creighton, Ludmila Danilova, L. Ding, G. Getz, P. Hammerman, D. Hayes, Bryan Hernandez, J. Herman, J. Heymach, I. Jurisica, R. Kucherlapati, D. Kwiatkowski, M. Ladanyi, Gordon Robertson, N. Schultz, R. Shen, Rileen Sinha, C. Sougnez, M. Tsao, W. Travis, J. Weinstein, D. Wigle, M. Wilkerson, Andy Chu, A. Cherniack, Angela Hadjipanayis, Mara Rosenberg, D. Weisenberger, P. Laird, Amie Radenbaugh, Singer Ma, Joshua Stuart, Lauren Byers, S. Baylin, R. Govindan, M. Meyerson, Mara Li, S. Gabriel, K. Cibulskis, Jaegil Kim, C. Stewart, Lee Lichtenstein, E. Lander, M. Lawrence, Cyriac M, C. Kandoth, R. Fulton, L. Fulton, M. McLellan, R. Wilson, K. Ye, C. Fronick, Christopher Maher, Christopher Miller, M. Wendl, Christopher Cabanski, E. Mardis, C. Wheeler, David Wheeler, Miruna Dhalla, M. Balasundaram, Y. Butterfield, R. Carlsen, E. Chuah, Noreen Dhalla, R. Guin, Carrie Hirst, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, J. Schein, Payal Sipahimalani, Angela Tam, R. Varhol, A. Robertson, N. Wye, N. Thiessen, R. Holt, Steven Jones, M. Marra, Joshua Hodi, M. Imieliński, R. Onofrio, Eran Hodis, Travis Zack, E. Helman, Chandra Pedamallu, J. Mesirov, G. Saksena, S. Schumacher, S. Carter, L. Garraway, R. Beroukhim, Angela Re, Semin Lee, Harshad Mahadeshwar, A. Pantazi, A. Protopopov, X. Ren, S. Seth, Xingzhi Song, Jiabin Tang, Lixing Yang, Jianhua Zhang, Peng-Chieh Chen, Michael Parfenov, Andrew Xu, Netty Santoso, L. Chin, Peter Park, Katherine T, K. Hoadley, J. Auman, S. Meng, Yan Shi, Elizabeth Buda, S. Waring, Umadevi Veluvolu, Donghui Tan, P. Mieczkowski, Corbin Jones, J. Simons, Matthew Soloway, T. Bodenheimer, S. Jefferys, J. Roach, A. Hoyle, Junyuan Wu, S. Balu, Darshan Singh, J. Prins, J. Marron, J. Parker, C. Perou, Jinze Liu, Leslie Bootwalla, D. Maglinte, Philip Lai, M. Bootwalla, D. Berg, Timothy Jr, Mara Mallard, Juok Cho, D. Dicara, David Heiman, Pei Lin, William Mallard, Douglas Voet, Hailei Zhang, L. Zou, M. Noble, N. Gehlenborg, H. Thorvaldsdóttir, Marc-Danie Nazaire, Jim Robinson, William Gross, B. Aksoy, G. Ciriello, B. Taylor, Gideon Dresdner, Jianjiong Gao, Benjamin Gross, V. Seshan, B. Reva, Rileen Sinha, S. Sumer, Nils Weinhold, C. Sander, Sam Haussler, S. Ng, Jingchun Zhu, C. Benz, C. Yau, D. Haussler, P. Spellman, Matthew Perou, P. Kimes, Bradley Liu, B. Broom, Jing Wang, Yiling Lu, Patrick Ng, L. Diao, Wenbin Liu, C. Amos, R. Akbani, G. Mills, Erin Gardn, Erin Curley, J. Paulauskis, Kevin Lau, S. Morris, T. Shelton, D. Mallery, J. Gardner, R. Penny, Charles Tarvin, Charles Saller, Katherine Tarvin, W. Richards, Robert Bryant, R. Cerfolio, A. Bryant, Daniel Farver, D. Raymond, N. Pennell, C. Farver, Christine Raben, Christine Czerwinski, L. Huelsenbeck-Dill, M. Iacocca, N. Petrelli, B. Rabeno, Jennifer Brown, Thomas Bauer, Oleg Nemirovich-Dan, O. Dolzhanskiy, O. Potapova, D. Rotin, Olga Voronina, Elena Nemirovich-Danchenko, K. Fedosenko, Anthony Sica, A. Gal, M. Behera, S. Ramalingam, G. Sica, Douglas Weaver, D. Flieder, J. Boyd, J. Weaver, Bernard Thinh, B. Kohl, Dang Thinh, G. Sandusky, Hartmut Juhl, E. Duhig, Peter Brock, P. Illei, E. Gabrielson, James Shin, Beverly Lee, Kristen Rodgers, D. Trusty, M. Brock, Christina Sullivan, C. Williamson, E. Burks, K. Rieger-Christ, A. Holway, T. Sullivan, Dennis Kosari, M. Asiedu, F. Kosari, William Rusch, N. Rekhtman, M. Zakowski, V. Rusch, Paul Owusu-Sarpong, Paul Zippile, James Suh, H. Pass, C. Goparaju, Y. Owusu-Sarpong, John Albert, John Bartlett, S. Kodeeswaran, J. Parfitt, H. Sekhon, Monique Albert, John Myers, J. Eckman, J. Myers, Richard Gaudioso, R. Cheney, Carl Morrison, Carmelo Gaudioso, Jeffrey Liptay, J. Borgia, P. Bonomi, M. Pool, M. Liptay, Fedor Zaytseva, F. Moiseenko, I. Zaytseva, Hendrik Muley, H. Dienemann, M. Meister, P. Schnabel, T. Muley, M. Peifer, Carmen Egea, C. Gomez-Fernandez, Lynn Herbert, Sophie Egea, Mei Kimryn, Mei Huang, L. Thorne, L. Boice, Ashley Salazar, W. Funkhouser, W. Rathmell, Rajiv Siegfried, R. Dhir, S. Yousem, S. Dacic, F. Schneider, J. Siegfried, R. Hajek, Mark Meyers, M. Watson, Sandra McDonald, B. Meyers, Belinda Bowman, B. Clarke, I. Yang, K. Fong, L. Hunter, M. Windsor, R. Bowman, Solange Letovanec, Solange Peters, I. Letovanec, K. Khan, Mark Pot, M. Jensen, E. Snyder, Deepak Srinivasan, A. Kahn, J. Baboud, D. Pot, Kenna Tarnuz, Kenna Shaw, Margi Sheth, Tanja Davidsen, John Demchok, Liming Yang, Zhining Wang, R. Tarnuzzer, Jean Zenklusen, Bradley Sofia, B. Ozenberger, H. Sofia, William Illei, E. Duhig (2014)

Comprehensive molecular profiling of lung adenocarcinoma

Nature, 511

Jianbin Chen, Hechuan Yang, A. Teo, Lidyana Amer, F. Sherbaf, C. Tan, J. Alvarez, Bingxin Lu, Jia Lim, A. Takano, R. Nahar, Yin Lee, C. Phua, K. Chua, L. Suteja, P. Chen, M. Chang, T. Koh, B. Ong, D. Anantham, A. Hsu, A. Gogna, C. Too, Z. Aung, Y. Lee, Lanying Wang, T. Lim, A. Wilm, P. Choi, Poh Ng, C. Toh, W. Lim, Siming Ma, B. Lim, Jin Liu, W. Tam, A. Skanderup, J. Yeong, E. Tan, C. Creasy, D. Tan, A. Hillmer, W. Zhai (2020)

Genomic landscape of lung adenocarcinoma in East Asians

Nature Genetics, 52

(2006)

Ethnic and racial differences in the smokingrelated risk of lung cancer

( ZhangCZhangZZhangG, et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett 2020; 479: 31–41.32201203)

ZhangCZhangZZhangG, et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett 2020; 479: 31–41.32201203, ZhangCZhangZZhangG, et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett 2020; 479: 31–41.32201203

( WoodKHensingTMalikR, et al. Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review. JAMA Oncol 2016; 2: 805–812.27100819)

WoodKHensingTMalikR, et al. Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review. JAMA Oncol 2016; 2: 805–812.27100819

WoodKHensingTMalikR, et al. Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review. JAMA Oncol 2016; 2: 805–812.27100819, WoodKHensingTMalikR, et al. Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review. JAMA Oncol 2016; 2: 805–812.27100819

Kui Wu, Xin Zhang, Fuqiang Li, Dakai Xiao, Yong Hou, Shida Zhu, Dongbing Liu, X. Ye, M. Ye, Jie Yang, Libin Shao, H. Pan, Na Lu, Yuan Yu, Liping Liu, Jin Li, liyan Huang, Hailing Tang, Q. Deng, Yue Zheng, Lihua Peng, Geng Liu, X. Gu, P. He, Ying-ying Gu, Weixuan Lin, Huiming He, Guoyun Xie, Han Liang, Na An, Hui Wang, M. Teixeira, J. Vieira, W. Liang, Xin Zhao, Zhiyu Peng, F. Mu, Xiuqing Zhang, Xun Xu, Huanming Yang, K. Kristiansen, Jian Wang, N. Zhong, J. Wang, Pan-Hammarström Qiang, Jianxing He (2015)

Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas

Nature Communications, 6

( MillerKDNogueiraLMariottoAB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69: 363–385.31184787)

MillerKDNogueiraLMariottoAB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69: 363–385.31184787

MillerKDNogueiraLMariottoAB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69: 363–385.31184787, MillerKDNogueiraLMariottoAB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69: 363–385.31184787

( OkayamaHKohnoTIshiiY, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72: 100–111.22080568)

OkayamaHKohnoTIshiiY, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72: 100–111.22080568

OkayamaHKohnoTIshiiY, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72: 100–111.22080568, OkayamaHKohnoTIshiiY, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72: 100–111.22080568

Sudhanshu Shukla, Joseph Evans, Rohit Malik, Felix Feng, S. Dhanasekaran, Xuhong Cao, Guoan Chen, David Beer, Hui Jiang, A. Chinnaiyan (2017)

Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma

Journal Of The National Cancer Institute, 109

Junming Xu, Chunchao Zhang, Xiang Wang, Linhui Zhai, Yiming Ma, Y. Mao, Kun Qian, Changqing Sun, Zhiwei Liu, Shangwen Jiang, Minghui Wang, Lin Feng, Lei Zhao, Ping Liu, Bo Wang, Xin Zhao, Hui Xie, Xiaoyun Yang, Liyuan Zhao, Yafei Chang, Jin-hui Jia, Xijun Wang, Yimin Zhang, Yaru Wang, Yikun Yang, Zhixiang Wu, Longhai Yang, Bin Liu, Teng Zhao, Shengguo Ren, A. Sun, Yang Zhao, W. Ying, Fei Wang, Guangshun Wang, Yi Zhang, S. Cheng, J. Qin, X. Qian, Yi Wang, Jing Li, F. He, T. Xiao, Minjia Tan (2020)

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Cell, 182

A. Yoshizawa, Shinji Sumiyoshi, M. Sonobe, Masashi Kobayashi, M. Fujimoto, F. Kawakami, T. Tsuruyama, W. Travis, H. Date, H. Haga (2013)

Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients

Journal of Thoracic Oncology, 8

Junjun Wang, Qingyun Liu, S. Yuan, Weijia Xie, Yuan Liu, Y. Xiang, N. Wu, Long Wu, Xiangyu Ma, T. Cai, Yao Zhang, Zhi-fu Sun, Yafei Li (2017)

Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies

Scientific Reports, 7

S. Dearden, J. Stevens, Yi-long Wu, D. Blowers (2013)

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

Annals of Oncology, 24

Joshua Campbell, A. Alexandrov, Jaegil Kim, J. Wala, A. Berger, C. Pedamallu, S. Shukla, Guangwu Guo, Angela Brooks, Bradley Murray, M. Imieliński, Xin Hu, Shiyun Ling, R. Akbani, Mara Rosenberg, C. Cibulskis, A. Ramachandran, E. Collisson, David Kwiatkowski, M. Lawrence, J. Weinstein, R. Verhaak, Catherine Wu, P. Hammerman, A. Cherniack, G. Getz, Jean T, J. Zenklusen, J. Zhang, Ina Felau, John Demchok, Liming Yang, Zhining Wang, M. Ferguson, R. Tarnuzzer, C. Hutter, H. Sofia, T. Pihl, Yunhu Wan, Sudha Chudamani, Jia Liu, Charlie Sun, R. Naresh, Laxmi Lolla, Ye Wu, C. Creighton, W. Rathmell, J. Auman, S. Balu, T. Bodenheimer, D. Hayes, K. Hoadley, A. Hoyle, Corbin Jones, S. Jefferys, S. Meng, P. Mieczkowski, Lisle Mose, C. Perou, J. Roach, Yan Shi, J. Simons, Tara Skelly, Matthew Soloway, Donghui Tan, Junyuan Wu, Umadevi Veluvolu, J. Parker, M. Wilkerson, L. Boice, Mei Huang, L. Thorne, M. Noble, Hailei Zhang, David Heiman, Juok Cho, N. Gehlenborg, G. Saksena, Douglas Voet, Pei Lin, S. Frazer, L. Chin, M. Tsao, F. Allison, D. Chadwick, T. Muley, M. Meister, H. Dienemann, R. Kucherlapati, Peter Park, Jay Bowen, J. Gastier-Foster, M. Gerken, K. Leraas, T. Lichtenberg, N. Ramirez, L. Wise, E. Zmuda, Josh Stuart, E. Collisson, M. Peifer, David Kwiatkowski, Joshua Campbell, C. Sougnez, S. Schumacher, J. Shih, R. Beroukhim, Travis Zack, S. Gabriel, M. Meyerson, L. Byers, Tanja Davidsen, P. Laird, D. Weisenberger, D. Berg, M. Bootwalla, Phillip Lai, D. Maglinte, S. Baylin, J. Herman, Ludmila Danilova, L. Cope, D. Crain, Erin Curley, J. Gardner, Kevin Lau, D. Mallery, S. Morris, J. Paulauskis, R. Penny, C. Shelton, T. Shelton, M. Sherman, P. Yena, G. Mills, Maxim Artyomov, R. Schreiber, R. Govindan, M. Meyerson (2016)

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Nature genetics, 48

M. Alsaleem, G. Ball, M. Toss, S. Raafat, M. Aleskandarany, Chitra Joseph, A. Ogden, Shristi Bhattarai, P. Rida, F. Khani, M. Davis, O. Elemento, R. Aneja, I. Ellis, A. Green, N. Mongan, E. Rakha (2020)

A novel prognostic two-gene signature for triple negative breast cancer

Modern Pathology

Identification of genes upregulated in ALK-positive and EGFR/ journals

( ItoMMiyataYKushitaniK, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer 2018; 9: 1594–1602.30298562)

ItoMMiyataYKushitaniK, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer 2018; 9: 1594–1602.30298562

ItoMMiyataYKushitaniK, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer 2018; 9: 1594–1602.30298562, ItoMMiyataYKushitaniK, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer 2018; 9: 1594–1602.30298562

Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, R. Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei, Shuangshuang Mao, Yalong Wang, Xiaoli Feng, N. Sun, Yan Wang, Jie He (2020)

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.

Cancer letters

W. Fridman, F. Pagès, C. Sautès-Fridman, J. Galon (2012)

The immune contexture in human tumours: impact on clinical outcome

Nature Reviews Cancer, 12

M. Imieliński, A. Berger, P. Hammerman, Bryan Hernandez, Trevor Pugh, Eran Hodis, Jeonghee Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M. Lawrence, P. Stojanov, K. Cibulskis, Kyusam Choi, L. Waal, Tanaz Sharifnia, Angela Brooks, H. Greulich, S. Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansén, C. Ludwig, W. Engel‐Riedel, E. Stoelben, J. Wolf, C. Goparju, K. Thompson, W. Winckler, D. Kwiatkowski, B. Johnson, P. Jänne, V. Miller, W. Pao, W. Travis, H. Pass, S. Gabriel, E. Lander, Roman Thomas, L. Garraway, G. Getz, M. Meyerson (2012)

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Cell, 150

( HoshidaYBrunetJPTamayoP, et al. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One 2007; 2: e1195.)

HoshidaYBrunetJPTamayoP, et al. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One 2007; 2: e1195.

HoshidaYBrunetJPTamayoP, et al. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One 2007; 2: e1195., HoshidaYBrunetJPTamayoP, et al. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One 2007; 2: e1195.

Joshua Bates, R. Derakhshandeh, L. Jones, Tonya Webb (2018)

Mechanisms of immune evasion in breast cancer

BMC Cancer, 18

( RemarkRBeckerCGomezJE, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med 2015; 191: 377–390.25369536)

RemarkRBeckerCGomezJE, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med 2015; 191: 377–390.25369536, RemarkRBeckerCGomezJE, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med 2015; 191: 377–390.25369536

( SunJZhaoTZhaoD, et al. Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Ther Adv Med Oncol 2020; 12: 1758835920937904.)

SunJZhaoTZhaoD, et al. Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Ther Adv Med Oncol 2020; 12: 1758835920937904., SunJZhaoTZhaoD, et al. Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Ther Adv Med Oncol 2020; 12: 1758835920937904.

T. Isaka, H. Nakayama, H. Ito, T. Yokose, Kouzo Yamada, M. Masuda (2018)

Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery

BMC Cancer, 18

( ZhouCWuY-LChenG, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.21783417)

ZhouCWuY-LChenG, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.21783417, ZhouCWuY-LChenG, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.21783417

( FridmanWHPagèsFSautès-FridmanC, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.22419253)

FridmanWHPagèsFSautès-FridmanC, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.22419253

FridmanWHPagèsFSautès-FridmanC, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.22419253, FridmanWHPagèsFSautès-FridmanC, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.22419253

D. Hanahan, R. Weinberg (2011)

Hallmarks of Cancer: The Next Generation

Cell, 144

Z. Dong, Jia-Tao Zhang, S. Liu, J. Su, Chao Zhang, Z. Xie, Qing Zhou, H. Tu, Chongrui Xu, Li-xu Yan, Yu‐Fa Li, W. Zhong, Yi-long Wu (2017)

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

OncoImmunology, 6

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma:

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma: